Want to see STTK full AI Analyst Report?

Shattuck Labs (STTK) Price & Analysis

278 Followers

STTK Stock Chart & Stats

$8.06

$0.34(4.80%)

At close: Jul 24 4:00 PM EDT

$8.06

$0.34(4.80%)

Day’s Range― - ―

52-Week Range$1.72 - $8.33

Previous CloseN/A

Volume1.47M

Average Volume (3M)1.43M

Market Cap

$538.95M

Enterprise Value$695.04M

Total Cash (Recent Filing)$63.30M

Total Debt (Recent Filing)$2.67M

Price to Earnings (P/E)―

Beta1.88

Next Earnings

Nov 10, 2026

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.51

Shares Outstanding100,363,250

10 Day Avg. Volume1,280,058

30 Day Avg. Volume1,425,355

Financial Highlights & Ratios

PEG Ratio0.10

Price to Book (P/B)3.08

Price to Sales (P/S)253.99

P/FCF Ratio-6.36

Enterprise Value/Market Cap1.29

Enterprise Value/Revenue695.04

Enterprise Value/Gross Profit-92.56

Enterprise Value/Ebitda-14.18

Forecast

1Y Price Target

$15.40

Price Target Upside91.07% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-0.49

Revenue Forecast (FY)$105.00K

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low leverage gives Shattuck greater financial flexibility than a heavily indebted development-stage company. The sizable asset base and limited debt burden may help preserve strategic options while clinical programs advance, although continued losses could reduce that cushion over time.

Multi-Mechanism PlatformThe ARC platform is designed to address immune pathways through engineered fusion proteins that combine mechanisms in one candidate. This creates a potentially broad development foundation across oncology and autoimmune disease, supporting multiple future programs from a shared technology base.

Clinical Pipeline ProgressPositive Phase 1 results and movement toward a Phase 2b trial represent meaningful clinical advancement beyond early discovery work. Continued progression could improve the platform's development credibility and create clearer catalysts for partnerships, financing, or eventual commercialization.

Bears Say

Minimal Revenue ScaleRevenue remains too small and stagnant to support the company's operating base or demonstrate commercial traction. Until clinical programs produce meaningful collaboration, licensing, or product revenue, Shattuck will remain financially dependent on external funding and future development success.

Persistent Cash BurnSustained negative operating and free cash flow shows that ongoing research and development requires substantial external capital. Limited self-funding capacity can constrain program choices, increase reliance on financing, and expose shareholders to dilution as clinical spending continues.

Deep UnprofitabilityThe company remains far from break-even, with costs exceeding revenue even at the gross-profit level and substantial net losses continuing. Negative returns on equity indicate that capital is not yet generating earnings, leaving profitability dependent on successful clinical and commercial execution.

Shattuck Labs News

Shattuck Labs initiated with a Buy at UBS

UBS initiated coverage of Shattuck Labs (STTK) with a Buy rating and $17 price target The firm believes...

9d ago

STTK

Shattuck Labs price target raised to $14 from $11 at Wedbush

Wedbush analyst David Nierengarten raised the firm’s price target on Shattuck Labs (STTK) to $14 from $11 and...

18d ago

MRK

STTK

Shattuck Labs price target raised to $19 from $17 at Needham

Needham analyst Joseph Stringer raised the firm’s price target on Shattuck Labs (STTK) to $19 from $17 and...

18d ago

STTK

Shattuck Labs to evaluate SL-325 in Phase 2 trial, appoints Ravichandran as SVP

Shattuck Labs (STTK) announced its plans to evaluate SL-325 in a Phase 2 clinical trial in patients with...

19d ago

STTK

Shattuck Labs has positive readthrough from Merck data, says H.C. Wainwright

After Merck (MRK) presented Phase 2b data for tulisokibart in moderate-to-severe hidradenitis suppurativa at the EADV Congress and...

20d ago

MRK

STTK

Shattuck Labs management to meet with Piper Sandler

Meeting to be held on October 1 hosted by Piper Sandler. Published first on TheFly – the ultimate...

27d ago

STTK

Pantginis Maintains Buy on Shattuck as Merck TL1A/DR3 Data De-Risk SL-325; Price Target Reiterated at $14

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Shattuck Labs, retaining the price target of...

20d ago

STTK

Shattuck Labs initiated with a Strong Buy at Raymond James

Raymond James analyst Martin Auster initiated coverage of Shattuck Labs (STTK) with a Strong Buy rating and $18...

2M ago

STTK

Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone

Shattuck Labs, Inc. ($STTK) announced an update on their ongoing clinical study. Shattuck Labs, Inc. is launching a...

2M ago

STTK

Buy Rating Reaffirmed on Shattuck Labs as De-Risked SL-325 Strategy and Strong Cash Runway Support Unchanged $18 Price Target

In a report released today, Yigal Nochomovitz from Citi maintained a Buy rating on Shattuck Labs, with a...

2M ago

STTK

Analyst Reaffirms Buy on Shattuck Labs, Maintains $17 Price Target on TL1A Pipeline Progress

Joseph Stringer, an analyst from Needham, maintained the Buy rating on Shattuck Labs. The associated price target remains...

2M ago

STTK

Shattuck Labs price target lowered to $14 from $18 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Shattuck Labs (STTK) to $14 from $18...

2M ago

STTK

Shattuck Labs reports Q2 EPS (12c), consensus (12c)

As of June 30, 2026, cash and cash equivalents and short-term investments were $208.3M, as compared to $50.5...

2M ago

STTK

SpaceX initiated, PayPal upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

ACI

STTK FAQ

What was Shattuck Labs’s price range in the past 12 months?

Shattuck Labs lowest stock price was $1.72 and its highest was $8.33 in the past 12 months.

What is Shattuck Labs’s market cap?

Shattuck Labs’s market cap is $538.95M.

When is Shattuck Labs’s upcoming earnings report date?

Shattuck Labs’s upcoming earnings report date is Nov 10, 2026 which is in 21 days.

How were Shattuck Labs’s earnings last quarter?

Shattuck Labs released its earnings results on Aug 11, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.124 by $0.004.

Is Shattuck Labs overvalued?

According to Wall Street analysts Shattuck Labs’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shattuck Labs pay dividends?

Shattuck Labs does not currently pay dividends.

What is Shattuck Labs’s EPS estimate?

Shattuck Labs’s EPS estimate is -0.11.

How many shares outstanding does Shattuck Labs have?

Shattuck Labs has 100,363,250 shares outstanding.

What happened to Shattuck Labs’s price movement after its last earnings report?

Shattuck Labs reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.124. Following the earnings report the stock price went up 0.56%.

Which hedge fund is a major shareholder of Shattuck Labs?

Currently, no hedge funds are holding shares in STTK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shattuck Labs Stock Smart Score

Neutral

Fundamentals

Return on Equity

-43.57%

Trailing 12-Months

Asset Growth

242.80%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Shattuck Labs

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.

Shattuck Labs (STTK) Earnings & Revenues

Historic Earnings Reports

STTK Stock 12 Month Forecast

Average Price Target

$15.40

▲(91.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","10":"$10","15":"$15","20":"$20"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5,10,15,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.84,7.775384615384615,8.71076923076923,9.646153846153846,10.581538461538461,11.516923076923078,12.452307692307691,13.387692307692308,14.323076923076922,15.258461538461539,16.193846153846152,17.12923076923077,18.064615384615387,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.84,7.498461538461538,8.156923076923077,8.815384615384616,9.473846153846154,10.132307692307693,10.790769230769232,11.44923076923077,12.107692307692307,12.766153846153847,13.424615384615386,14.083076923076923,14.741538461538463,{"y":15.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.84,7.083076923076923,7.326153846153846,7.569230769230769,7.812307692307693,8.055384615384614,8.298461538461538,8.541538461538462,8.784615384615385,9.027692307692307,9.27076923076923,9.513846153846153,9.756923076923076,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.99,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.84,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >